Relevium Targets 83 Million Unique Monthly Visitors and 26 Countries Through European Expansion of Bioganix(R)
Momentum Public Relations
Press Release: April 5 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce that it has started the process of establishing European presence for the new Bioganix® brand in partnership with several online partners, including Amazon. Management will be doing an initial launch of eight best selling products, which will be live online on the week of the May 21, 2018 with full marketing launch by mid summer.
Highlights
- Bioganix® has started European expansion with online partners, including Amazon
- Initial launch of eight best selling products the week of May 21, 2018
Impact on the Business
- Presence in Europe adds 83M monthly unique visitors, over 200M new customers and access to 26 European Countries
- Increased competitive advantage and insulation from seasonality in sales
- Building the “trusted” Bioganix® brand equity internationally to a loyal consumer base
Impact on Shareholders
- Management is investing in growing its main retail asset internationally to deliver sustainable value to customers and shareholders alike
- Exposure of RLV to potential European equity investors through its Frankfurt listing
Aurelio Useche, CEO of Relevium, stated: “The decision to expand to Europe was driven by several key indicators including Amazon’s current investment in the region, access to 230M new customers buying online, higher basket sizes and lower competition. We believe the new Bioganix® brand is poised to gain customer acceptance as a “trusted” brand and successful consumer engagement in the European market”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
Relevium Technologies Inc.
+1.888.528.8687
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
- Published in Relevium Technologies
Stelmine reveals a new gold-rich zone on Courcy
Momentum Public Relations
Press Release: April 5 2018
Stelmine Canada(« Stelmine ») (TSX-V:STH) reveals the results of its last exploration campaign realized on a new zone located in the southern part of the Courcy property. In fact, our work including geological mapping, sampling and overburden stripping unhearted km-long structures and gold-bearing lithologies on which more detailed work certainly including diamond drilling will be completed during the 2018 summer season.
The Southern Zone presents several geological features that warrant a more thorough investigation:
- Visible gold observed on at least three major showings;
- High gold values associated with pyrrhotite-rich deformed/mylonitic metasedimentary/metavolcanic rocks: ex. 167 g/t, 33 g/t, 24.8 g/t and 4.8 g/t;
- Gold assay values ranging from 0.36 to 24.8 g/tAu and averaging 2.75 g/t (41 samples excluding the 167 g/t sample);
- The reinterpretation of past geophysical surveys highlighted bent contours in magnetic/conductive signatures suggesting deformed structures susceptible to form traps for gold mineralization. These km-long folded features (mylonites and shears) are rich in pyrrhotite ± pyrite ± chalcopyrite±gold;
- The widespread occurrence of conglomeratic units combined with the presence of fuchsite associated with sulfide-rich rocks, ultramafic sills, silicified protoliths and quartzite/arenitic bands, all suggest widespread hydrothermal alteration possibly associated with gold mineralization.
The Courcy property consists of 393 claims located in the eastern segment of the Opinaca sub-province near the Quebec/Labrador border, 100 km west of the city of Fermont, Quebec.
The technical contents of this release were approved by Michel Boily, PhD, geo; a Qualified Person (QP) as defined by National Instrument 43-101.
Follow us on www.Stelmine.com and on our Facebook page (Stelmine Canada) where we uploaded pictures of the Courcy camp and of our crew at work.
About Stelmine
Stelmine is a junior mining exploration company which concentrates its activities in the Province of Québec. Stelmine holds 838 claims spanning 583 km2 on the eastern part of the Opinaca metasedimentary basin, which contains zones with a high potential for gold deposit discovery in geological contexts similar to the one leading to discovery of the Éléonore Mine. Its capital stock consists of 23,680,645 issued and outstanding shares for a current market capitalization of $3.9 million.
Forward-looking statements
The statements set forth in this press release, which describes Stelmine’s objectives, projections, estimates, expectations or forecasts, may constitute forward-looking statements within the meaning of security legislation. Positive or negative verbs such as “believe”, “can”, “shall”, “intend”, “expect”, “estimate”, “assume” and other related expressions are used to identify such statements. Stelmine wishes to state that, by their very nature, forward-looking statements involve risks and uncertainties such that its results, or the measures it adopts, could differ materially from those indicated or underlying these statements or could have an impact on the degree of realization of a particular projection. Major factors that may lead to a material difference between Stelmine’s actual results and the projections or expectations set forth in the forward-looking statement include the risk that the Company does not complete the Placement as anticipated, and such other risks as described in detail from time to time in the reports filed by Stelmine with security authorities in Canada. Unless otherwise required by applicable securities laws, Stelmine disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of the new information, future events or otherwise. The forward-looking information in this release is based on information available as of the date of this release.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For more information :
Isabelle Proulx President and CEO |
Christian Guilbaud Business Development |
581-998-1222 info@stelmine.com |
514-813-7862 |
Stelmine.com |
- Published in Stelmine Canada, Uncategorized
Corex Gold Receives Overwhelming Shareholder Approval for Plan of Arrangement With Minera Alamos Inc.
Corex Gold Corporation (“Corex” or the “Company”) (TSX-V:CGE) is pleased to announce that shareholders of the Company have overwhelmingly voted in favour of the previously announced plan of arrangement (the “Arrangement”) with Minera Alamos Inc. (TSX Venture:MAI), see press release dated January 30th 2018.
A total of 71,679,327 common shares of the Company, representing approximately 45.25% of the Company’s issued and outstanding common shares were voted. The Arrangement was approved by 100% (due to rounding) of the votes cast by Corex shareholders (including disinterested shareholders). A copy of the complete report on voting will be made available on SEDAR at www.sedar.com.
A summary of the voting results is presented below:
Total Votes FOR: | 71,677,817 | Total Votes AGAINST: | 1,510 |
Disinterested Votes FOR: | 61,166,237 | Disinterested Votes AGAINST: | 1,510 |
The Arrangement is expected to close on or about April 10, 2018 resulting in Corex becoming a wholly owned subsidiary of Minera Alamos with the former shareholders of Corex thereafter owning approximately 50% of Minera Alamos, The closing is subject to applicable regulatory approvals and the satisfaction of other customary conditions.
About Corex Gold Corporation
Corex Gold Corp is a Canadian resource company focused on developing its 100% owned Santana flagship property in Sonora State, Mexico, where recent bulk test leaching and development work has resulted in the first gold produced from the property.
For Further Information Please Contact: | ||||
Corex Gold Corporation | ||||
Doug Ramshaw | President & CEO | |||
Tel: 236-521-0429 | Email: doug@corexgold.com | Website: www.corexgold.com | ||
Cautionary Statement Regarding Forward-Looking Information
This news release includes certain “Forward‐Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward‐looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward‐looking statements or information. These forward‐looking statements or information relate to, among other things: anticipated timing of closing of the Arrangement.
These statements reflect the Company’s respective current views with respect to future events and are necessarily based upon a number of other assumptions and estimates that, while considered reasonable by the Company, are inherently subject to uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements or forward-looking information and Corex has made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: satisfaction or waiver of all applicable conditions to closing of the Arrangement including, without limitation, receipt of all necessary court, stock exchange and regulatory approvals or consents and lack of material changes with respect to Minera Alamos and Corex and their respective businesses, all as more particularly set forth in the Arrangement Agreement. Readers are cautioned against attributing undue certainty to forward‐looking statements or forward-looking information. Although the parties have attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be anticipated, estimated or intended. Corex does not intend, and does not assume any obligation, to update these forward‐looking statements or forward-looking information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements or information, other than as required by applicable law.
- Published in Corex Gold
Tetra Bio-Pharma Initiates Enrolment of Patients in Phase 3 PPP001 Smokable Cannabis Pellet Study
Momentum Public Relations
Press Release: April 4 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced the initiation of screening and enrolment activities in the Phase 3 study of its PPP001 smokable cannabis pellet for advanced cancer patients with uncontrolled pain.
Tetra authorized the initiation of the patient enrolment activities at its main clinical site, Santé Cannabis, a private medical cannabis clinic in Montreal which is in compliance with Health Canada Division 5 regulations and the International Conference on Harmonization (ICH) Good Clinical Practices (GCP) (E6) R2.
PPP001 aims to be the first smokable cannabis for advanced cancer pain available under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9.5% THC and 2.5% CBD.
“This is a significant milestone in the lead product of our strong pipeline of cannabinoid-based drugs targeting patients with advanced pain,” said Guy Chamberland, Tetra’s CEO and CSO. “The launch of the Phase 3 clinical trial will be used to support the marketing application of PPP001 smokable pellet that is followed by four other cannabinoid-based products that we are developing using different delivery systems such as oral tablets, eye drops, topical ointments and oral capsules of cannabis oil.”
On February 28th, 2018, Santé Cannabis received authorization from the Office of Controlled Substances to use PPP001 (controlled substance) for the Phase 3 clinical trial. This authorization granted the Principal Investigator of the Phase 3 trial, Dr. Antonio Vigano, exemption from the application of several provisions of the Controlled Drugs and Substances Act and the Narcotic Control Regulations thereby allowing the investigator to proceed with the clinical study of PPP001 in advanced cancer patients. In addition, the exemption allows Santé Cannabis to store and dispense the study medication directly to the patients, a process not permitted by Licensed Producers under the ACMPR.
“We are performing the first large study of the safety and efficacy of a dried cannabis smoked drug in advanced cancer patients,” added Guy Chamberland. “Over the next month Tetra will expand the trial by working with other clinics across Canada. Most importantly, we believe this multisite study has the potential to change the current vision of the use of smoked cannabis as an effective palliative care therapy of patients with advanced cancer.”
About PPP001:
PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9.5% THC and 2.5% CBD.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575
For media information, please contact:
Daniel Granger
Daniel.granger@acjcommunication.com
ACJ Communication
O: 1 514 840 7990
M: 1 514 232 1556
For investors information, please contact:
investors@tetrabiopharma.com
(438) 504-5784
- Published in Tetra Bio Pharma
Pacton Gold Receives TSX Venture Exchange Acceptance to CTTR Gold Pty Ltd. Acquisition
Momentum Public Relations
Press Release: April 3 2018
Pacton Gold Inc. (TSXV: PAC, OTC: PACXF) (the ” Company ” or ” Pacton “) is pleased to announce that further to its news release of February 26, 2018, it has received TSX Venture Exchange acceptance for an option to acquire 100% of the issued and outstanding shares of CTTR Gold Pty Ltd (” CTTR “). CTTR holds applications to nine tenement licenses for a strategic mineral property group (the ” Property “) in the Pilbara Region of Western Australia. The 492 km 2 Property is an advanced gold project portfolio that will target conglomerate gold occurences within the eastern extension of the Pilbara conglomerate gold play. One priority will be to explore for a northern extension of DeGrey’s Mallina Basin occurences that include 5 to 80 m thick gold nugget conglomerate beds at Loudens Patch, Jarret Well and Steel Well.
See property map at http://pactongold.com/Pacton_Aus_Regional_Fig1.pdf .
Pacton has commenced compiling and reviewing historical reports and data on the Property and collating other available datasets prior to planning a first-pass field evaluation programme, which will likely comprise of detailed mapping to define key stratigraphic units, rock-chip, soil and stream sediment sampling and metal detecting.
Pacton intends to initiate negotiations with the relevant Native Title representative bodies, representing an intergral step towards the Company’s tenement license applications being granted by the Department of Mines, Industry Regulation and Safety. The Company will commence the heritage notice process to allow for tenure to be cleared for on-ground exploration activities.
Under the terms of the agreement with CTTR, the Company paid $75,000 and issued 916,666 common shares and 458,333 share purchase warrants. Each warrant is exercisable into one common share for a period of 18 months from the date of issue at a price of $0.45 per share.
Upon grant of six key exploration licenses, the Company must pay a further $50,000 and issue 416,666 common shares and 208,333 share purchase warrants. Each warrant will be exercisable into one common share for a period of 18 months from the date of issue with an exercise price equal to 150% of the 5-day trading volume weighted average price of the Company’s shares, subject to a floor price of not less than the $0.24.
All monetary amounts referred to herein are in Canadian currency.
The Company issued 156,250 common shares to COMVERJ Pty Ltd. as a finder’s fee with respect to the transaction.
The Company also announces that further to its news release of March 14, 2018, it has issued 1,833,333 common shares in payment of outstanding debt and confirms that debt of $550,000 has now been extinguished.
About Pacton Gold
Pacton Gold Inc. (TSXV: PAC) is a Canadian junior exploration company focused on acquiring, exploring and advancing mineral assets in key mining friendly locations globally.
On Behalf of the Board of Pacton Gold Inc.
Alec Pismiris
Interim President & CEO
For more information, please contact 1-(855)-584-0258 or dom@pactongold.com .
This news release may contain or refer to forward-looking information based on current expectations, including, but not limited the prospect of the Company achieving success in exploring the Property and the impact on the Company of these event, including the effect on the share prices. References to other companies with proximal exploration properties in the Pilbara region is for information only and there are no assurances that the Company will achieve results similar to other companies in the region. Forward-looking information is subject to significant risks and uncertainties, as actual results may differ materially from forecasted results. Forward-looking information is provided as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances .
- Published in Pacton Gold Inc.
Relevium Announces All-Time Record High of Units Sales for Bioganix(R) in March
Momentum Public Relations
Press Release: April 3 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to report an all-time record high in unit sales for the month of March 2018.
The reported record high of 16,549 units, which was achieved in a seasonally low period, reflects increased online demand for the Bioganix® established product line, which is expected to translate into sales in excess of $439,000 for the month of March. The monthly high did not include the effect from new product launches, which are expected to have an incremental positive impact over the next six months.
The company’s all-time record high of units sold is an important achievement for Relevium’s Bioganix®brand. The Company continues to increase its subscriber base and number of SKUs, now totaling over 230,000 and 38 respectively.
Impact on the Business
- Increase of Bioganix® demand sets the stage for successful launch of new products
- The results indicate that the company’s investment in Mach 2.0 Marketing Engine is starting to pay dividends
Impact on Shareholders
- Increased confidence that management remains engaged on delivering sustainable value to its brands, customers and shareholders
- Incremental value to the acquired Bioganix® business through increased brand equity, exclusive product lines and geographic expansion
- Relevium is steadily building solid base for shareholder value creation, which will deliver future dividends
Abis Hussain, SMO of Relevium, stated: “The implications of this may seem trivial, but the results form this month in a seasonally low period indicate that Mach 2.0 is working as designed. We expect this to also have a positive impact on new products launches over the next six months.”
Aurelio Useche, CEO of Relevium, stated: “This is the first real test of the capabilities of our marketing engine following months of adjustments and beta testing. This small but important success is an important achievement for the company and for our digital marketing and operating teams.”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
RELEVIUM TECHNOLOGIES INC
Relevium Technologies Inc.
Aurelio Useche
President and CEO
+1.888.528.8687
investors@releviumcorp.com
www.releviumtechnologies.com
- Published in Relevium Technologies